Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency

NCT01554514 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT01554514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01554514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Low Dose Rituximab for Acquired TTP With Severe ADAMTS13 Deficiency
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2012
Completion date
February 14, 2020
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

thrombotic thrombocytopenic purpura